Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...

合作与财务 - Werewolf Therapeutics与Jazz签署了独家全球许可协议，获得1500万美元的预付款，并有资格获得高达5.2亿美元的开发和监管里程碑付款，以及高达7.4亿美元的基于销售的里程碑付款[10] - 公司在2023年第四季度之前拥有充足的现金流，确保运营持续性[43] 产品研发与临床进展 - WTX-124 IL-2 INDUKINE分子预计将在2022年第二季度提交IND申请[11] - WTX-330 IL-12 INDUKINE分子预计将在2022年提交IND申请，目标是快速实现概念验证[23] - WTX-613 IFNα INDUKINE分子用于固体肿瘤和血液恶性肿瘤的单药治疗及与标准治疗的联合治疗[9] - IL-12 INDUKINE治疗显著增加了肿瘤特异性TIL（肿瘤浸润淋巴细胞）数量，CD8+ T细胞多功能性提高至80%[17] - 在MC38肿瘤模型中，IL-12 INDUKINE的治疗指数超过40，而重组IL-12的治疗指数为2[26] - IL-12 INDUKINE治疗后，肿瘤体积在治疗开始后15天内显著减少，达到1500 mm³以下[38] - 在抗PD-1耐药的肿瘤模型中，mWTX-330显示出良好的抗肿瘤活性，肿瘤体积在治疗后显著下降[35] - WTX-124 IL-2 INDUKINE疗法在MC38小鼠肿瘤模型中显示出优越的抗肿瘤活性，肿瘤体积显著减少[13] - WTX-124 IL-2 INDUKINE疗法在肿瘤微环境中选择性释放全效能IL-2，保留了IL-2的完整药理特性[15] - 公司正在进行的发现项目专注于免疫肿瘤学[9] - WTX-124和WTX-330的单药和联合治疗扩展队列正在进行中，针对免疫敏感肿瘤类型[20] - 预计在2022年进行初步数据发布，进一步验证治疗效果[44] 风险与展望 - 公司预计在未来的临床开发中将面临多种风险和不确定性，包括产品候选药物的开发和监管批准的时间[1] - 公司在2022年5月10日向美国证券交易委员会提交的季度报告中列出了相关风险因素[1] - 公司可能会更新前瞻性声明，但明确表示没有义务这样做[1] 战略合作 - 公司与默克（Merck）达成KEYTRUDA®临床合作，进一步推动临床开发[43] - 公司已获得多项专利，推动发现管道的进展[44]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-K ______________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Delaware 82-3523180 (State or other jurisdiction of incorporation or organization) 1030 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...